Liquidia Corp Investor Relations Material

Liquidia Corp. is a biopharmaceutical company focused on developing and commercializing innovative therapies for pulmonary and other rare diseases. The company utilizes its proprietary PRINT technology to engineer precise drug particles designed to improve the delivery and efficacy of inhaled treatments. Liquidia's primary focus is on addressing unmet medical needs in pulmonary arterial hypertension (PAH) and other related conditions. The company is involved in advancing its therapies through clinical trials and regulatory approvals, aiming to provide improved treatment options for patients with chronic, life-threatening illnesses. The company is headquartered in Morrisville, North Carolina, and its shares are listed on the NASDAQ.